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Abstract
Background: Perturbations on the Left-Right axis establishment lead to laterality defects, with frequently associated
Congenital Heart Diseases (CHDs). Indeed, in the last decade, it has been reported that the etiology of isolated cases of
CHDs or cases of laterality defects with associated CHDs is linked with variants of genes involved in the Nodal signaling
pathway.
Methods: With this in mind, we analyzed a cohort of 38 unrelated patients with Congenital Heart Defects that can arise
from initial perturbations in the formation of the Left-Right axis and 40 unrelated ethnically matched healthy individuals
as a control population. Genomic DNA was extracted from buccal epithelial cells, and variants screening was performed
by PCR and direct sequencing. A Nodal-dependent luciferase assay was conducted in order to determine the functional
effect of the variant found.
Results: In this work, we report two patients with a DAND5 heterozygous non-synonymous variant (c.455G > A) in the
functional domain of the DAND5 protein (p.R152H), a master regulator of Nodal signaling. Patient 1 presents left
isomerism, ventricular septal defect with overriding aorta and pulmonary atresia, while patient 2 presents ventricular
septal defect with overriding aorta, right ventricular hypertrophy and pulmonary atresia (a case of extreme tetralogy of
Fallot phenotype). The functional analysis assay showed a significant decrease in the activity of this variant protein
when compared to its wild-type counterpart.
Conclusion: Altogether, our results provide new insight into the molecular mechanism of the laterality defects and
related CHDs, priming for the first time DAND5 as one of multiple candidate determinants for CHDs in humans.
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Background
Heart morphogenesis is a complex process involving
multiple cell types (cardiac and non-cardiac) thus requir-
ing a precise control of all molecular and cellular mech-
anisms [1]. Subtle deviations in heart development lead
to Congenital Heart Diseases (CHDs), which are the
most prevalent form of birth defect (postnatal incidence
of 0.8% of all newborns) and the leading non-infectious
cause of death in the first year of life [2, 3]. The etiology
of CHD is incompletely understood, thought to be
multifactorial, involving multiple genetic and environ-
mental factors, and the possible interactions between
those factors [4]. Nevertheless, in the last years, CHDs
are seen as disorders resulting from alterations in genes
that control basic embryonic processes between the
third and eighth week of gestation, when the majority of
the cardiovascular structures develop and when the in-
tegrity of the left-right (LR) axis is established [5, 6]. In
fact, in the majority of cases presenting laterality disor-
ders, a complex heart malformation is also observed,
suggesting that CHDs could be due to a laterality defect
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in the formation of the heart [7]. In others words, even
in children that born with CHDs and that do not present
others extracardiac laterality abnormalities, the etiology
of these CHDs could arise from subtle faults in the for-
mation of the left-right axis.
The molecular control of LR axis development is
mainly achieved by the Nodal signaling pathway [8].
Studies in mice revealed that during gastrulation, Nodal,
a growth factor from the TGF-ß family, is asymmetric-
ally expressed in the node, and this expression is ex-
panded and amplified in the left-lateral plate mesoderm
(L-LPM), but inhibited in the right-lateral plate meso-
derm (R-LPM) [9]. Nodal itself induces its intracellular
signaling by binding to type I (ALK4 and ALK7) and
type II (ActRIIa and ActRIIb) serine-threonine kinase re-
ceptors in the presence of one EGF-CFC (epidermal
growth factor-Cripto-FRL1-Cryptic) family co-receptor,
Cripto or Cryptic. This leads to the phosphorylation of
regulatory Smads (Smad2 and Smad3), their association
with Smad4, translocation into the nucleus, and to the
interaction with the transcription factor FoxH1, which at
the end activates the expression of Nodal target genes,
in particular, Pitx2 [9]. Pitx2 is a transcription factor that
regulates the fate of cells that will form the visceral or-
gans, including the heart [8, 10]. The impairment of the
Nodal signaling in the lateral plate mesoderm, by vari-
ants in the genes involved in the pathway such as
ActRIIB (MIM #602730) [11, 12], LEFTY 1 (MIM
#603037) [13, 14], LEFTY 2 (MIM #601877) [13, 14],
CRYPTIC/CFC1 (MIM #605194) [15, 16], CRIPTO/
TDGF1 (MIM #187395) [17, 18], FOXH1 (MIM
#603621) [19, 20], NODAL (MIM #601265) [21, 22] and
PITX2C (MIM # 601542) [23, 24] had already been asso-
ciated to laterality disorders and/or CHDs in humans.
For example, the heterozygous variant p.G260R in
NODAL was associated with transposition of the great
arteries (TGA), atrial and ventricular septal defects,
double outlet right ventricle (DORV) and/or heterotaxy
[21]. On the other hand, the NODAL p.S60I variant has
been associated with the tetralogy of Fallot (TOF)
phenotype [22]. Additionally, several variations in Nodal
co-receptor CFC1 were linked to TOF, TGA, DORV
and/or laterality defects [15, 17, 25].
Recently, we reported that a DAN family member, the
Nodal antagonist Cerberus-like 2 (Cerl2) – DAND5 in
humans (MIM #609068; refseq - NM_152654.2) – con-
trols Nodal signaling at the mouse node [26, 27], and
the transmission of LR asymmetry information to the
left-lateral plate mesoderm in a precise time window
[28, 29]. Furthermore, the absence of Cerl2 in Cerl2 KO
embryos leads to a range of laterality defects and/or car-
diovascular malformations such as incomplete atrial and
ventricular septation, TGA, DORV, randomized posi-
tioning of the cardiac apex, ventricular hypertrophy and/
or heterotaxy of the abdominal organs, and a significant
mortality rate within a few hours after birth is observed
[30, 31].
Here, in order to advance the understanding of
DAND5 in the genetic etiology of laterality disorders
and associated CHDs, we conducted a genetic screening
to identify DAND5 allelic variants in children affected
with CHDs and/or LR asymmetry defects. We identified
a DAND5 allelic variant in two patients, which was ab-
sent in the referral chromosomes from an ethnically
matched control population that reduces the inhibitory
activity of DAND5. We suggest that this variant might




This study was conducted in accordance with the ethical
principles of the revised Declaration of Helsinki. The re-
search protocol was approved by the local institutional
ethics committee of Hospital de Santa Cruz, Centro
Hospitalar de Lisboa Ocidental, E.P.E., Hospital de Faro,
Centro Hospitalar do Algarve, E.P.E., Hospital Sta.
Marta, Centro Hospitalar de Lisboa Central, E.P.E. and
NOVA Medical School. The Research Project was ap-
proved by the National Committee for Data Protection
(Authorization N.° 8694/2016). Written informed con-
sent was obtained from all guardians participants prior
to the collection of the DNA.
Clinical evaluation and inclusion criteria
The study sample included 38 Caucasian unrelated
pediatric patients with congenital heart defects arising
from possible left-right defects recruited from three
Portuguese hospitals, Hospital de Santa Cruz, Centro
Hospitalar de Lisboa Ocidental, E.P.E., Hospital de Faro,
Centro Hospitalar do Algarve, E.P.E., Hospital Sta.
Marta, Centro Hospitalar de Lisboa Central, E.P.E. The
sample was obtained at the time of the appointment ac-
cording to the convenience and availability of physicians
in each hospital. A total of 40 ethnically matched unre-
lated individuals were recruited as control samples to
screen for the identified variant in DAND5.
Patients were evaluated by individual and familial his-
tory, review of the medical records and individual
anatomic descriptions of the patients’ defects were ob-
tained by the review of echocardiogram, echocardiog-
raphy, magnetic resonance imaging, angiography or
direct view during cardiac surgery. Taking into account
the phenotype of the Cerl2 KO mice, in which 35% of
the homozygous mutants died within the first 48 h after
birth due to several cardiovascular malformations, in-
cluding incomplete atrial and ventricular septation, con-
otruncal defects, ventricular hypertrophy, and/or to
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laterality defects like left isomerism and thoracic hetero-
taxy or situs inversus, the inclusion criteria required the
presence of congenital heart malformations and/or lat-
erality defects, namely left or right isomerism; hetero-
taxy; situs inversus; transposition of great arteries
(TGA); double inlet left ventricle (DILV); double outlet
right ventricle (DORV); tetralogy of Fallot or Fallot like
phenotype; atrioventricular septal defects (AVSD); atrial
septal defects (ASD); ventricular septal defects (VSD)
and ventricular hypertrophy. The patients with known
chromosomal abnormalities or syndromic cardiovascular
defects, such as Down syndrome, Turner syndrome,
Marfan syndrome, Di George syndrome, and Holt–
Oram syndrome, were excluded from the study.
The clinical characteristics of the cohort of patients
that participated in the study are summarized in Table 1.
Genetic screening of DAND5 gene
Genomic DNA from the buccal epithelial cells of all par-
ticipants was extracted using the Isolate Genomic DNA
mini kit (BIOLINE) according to the manufacturer’s in-
structions for DNA isolation from buccal swabs. The
coding exons and flanking exon–intron boundaries of
the DAND5 gene were sequenced in 38 Caucasian
unrelated patients with CHDs and/or laterality defects
and in 40 ethnicity- and geographic-matched controls.
The referential genomic DNA sequence of DAND5 was
derived from Ensembl (http://www.ensembl.org), acces-
sion number ENST00000317060. Primer-BLAST pro-
gram (http://www.ncbi.nlm.nih.gov/tools/primer-blast/)
was used to design the primer pairs utilized to amplify
the coding regions and splice junction sites of DAND5,




GTCTTTCTTGGTCCATCTC-3′. The PCR was carried
out using 10–30 ng of genomic DNA in a 25 μL reaction
containing 1X Phusion HF Buffer (ThermoScientific),
0.5 μM of each primer, 0.2 mM dNTPs and 0.02 U/μL of
Phusion High-Fidelity DNA polymerase (ThermoScienti-
fic). PCR cycling was performed on C1000 Thermal
Cycler (Bio-Rad) using a denaturation cycle at 98 °C for
1 min followed by 35 cycles of denaturation at 98 °C for
15 s, annealing of primers for 30 s and extension at 72 °C
for 30 s and a final extension step at 72 °C for 5 min. Both
strands of each PCR product were sequenced with an ABI
Prism 3130 automated genetic analyzer (Applied Bio-
systems) according to the protocols from the Sequencing
Service of CCMAR (http://www.ccmar.ualg.pt/). The
DNA sequences were analyzed by BioEdit Sequence
Alignment Editor Software. The identified DAND5 variant
was confirmed by sequencing three independent PCR-
generated amplicons from the same patient. Addition-
ally, the identified sequence variation was queried in
the single nucleotide polymorphism (SNP) database at
NCBI (https://www.ncbi.nlm.nih.gov/), the human gene
mutation (HGM) database (http://www.hgmd.org/), the
1000 Genome Project (1000 GP) database (http://
www.1000genomes.org/), and the ExAC consortium
(http://exac.broadinstitute.org/) to confirm its novelty.
Screening for alterations in other known genes associ-
ated to CHD / laterality was not conducted in our pa-
tients and control cohorts.
Sequence alignment of DAND5 among vertebrate species
Conservation of the amino acid altered by the missense
allelic variant was estimated by aligning the human
DAND5 protein to chimpanzee, rat, mouse, xenopus
and zebrafish using Clustal Omega program from Uni-
prot (http://www.uniprot.org/).
Characterization of the causative potential of p.R152H
variation
The potential effect of the p.R152H DAND5 variation
was characterized by the software programs Poly-
phen − 2 (http://genetics.bwh.harvard.edu/pph2/) Mu-
tation Taster (www.mutationtaster.org), PROVEAN
Table 1 Clinical characteristics of the patients genotyped
Prevalence of different types of CHD Patients (n = 38)
Atrial septal defect 2 (~5%)
Ventricular septal defect 11 (~29%)
Atrioventricular septal defects 8 (~21%)
Conotruncal defects
Pulmonary atresia/stenosis 14 (~37%)
Tetralogy of Fallot 7 (~18%)
Transposition of the great arteries 8 (~21%)
Double inlet left ventricle 2 (~5%)
Double outlet right ventricle 1 (~3%)
Aortic coarctation 1 (~3%)
Overriding aorta 1 (~3%)
Left isomerism 4 (~11%)
Right isomerism 1 (~3%)
Dextrocardia 3 (~8%)
Other cardiac malformations 20 (~53%)
Extracardiac abnormalities
Situs inversus totalis 1 (~3%)
Visceral situs inversus 1 (~3%)
Asplenia 1 (~3%)
Other cardiac malformations included right sided aortic arch, inferior vena
cava interruption, univentricular heart, aortic stenosis, mitral valve stenosis,
tricuspid atresia, hypoplastic right ventricle, hypoplastic left heart, major
aortopulmonary collateral artery, persistent left superior vena cava, single
ventricle, total anomalous pulmonary venous connection. Note: Almost all the
patients have more than one type of CHD
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(http://provean.jcvi.org/), and I- Mutant 3.0 (http://
gpcr2.biocomp.unibo.it/cgi/predictors/I-Mutant3.0/I-
Mutant3.0.cgi). The outcome of all tests was either a
disease mutation or a harmless polymorphism.
Polyphen-2 utilizes a combination of sequence, func-
tion, evolutionary conservation and structure based
attributes and uses naive Bayesian classifier to deter-
mine the effect of an amino acid alteration. The output
levels of damaging in the protein were classified as
deleterious (≤ 0.5) and the benign level being classified
as tolerated (≥ 0.51). Mutation Taster software’s analysis
are based on protein structure/function and evolution-
ary conservation and employs a Bayes classifier to even-
tually predict the disease potential of an alteration.
PROVEAN based analysis takes into account the align-
ment and measurement of similarity between variant
sequence and protein sequence homolog, and the out-
put classifies the alteration as deleterious (≤ −2.5) or
neutral (≥ 2.51). I-Mutant 3.0 is a support vector machine-
based tool that predicts the stability change of a mutated
protein. The output prediction classifies the alteration in 3
classes: neutral alteration (− 0.5 ≤ DDG ≤ 0.5 kcal/mol),
large decrease of stability (≤ − 0.5 kcal/mol) and large
increase of stability (> 0.5 kcal/mol).
Plasmids and site-directed mutagenesis
The encoding full-length human DAND5 (IRCMp50
12B019D) was purchased from Source BioScience Life-
Sciences, Nottingham, United Kingdom. The c.455G > A
variant was generated by site-directed mutagenesis using
the QuikChange kit (Stratagene, La Jolla, CA, USA) and
the following pair of primer: Forward: 5′ GTATGCCT
GCTCACAAGCGTTGGG 3′; Reverse: 5’CCCAACGC
TTGTGAGCAGGC 3′ according to the manufacturer’s
instructions. The recombinant expression vectors hNO-
DAL-pcDNA and hCRIPTO-pEF6/V5-His TOPO were
kindly provided by Dr. Michael R Kuehn from Center
for Cancer Research, National Cancer Institute, Bethesda,
Maryland and the FoxH1 plasmid was provided by An
Zwijsen from KU Leuven. The plasmids were subcloned
into the expression vector pCS2+ vector to ensure the
same backbone plasmid for each gene.
Luciferase assay
Human embryonic kidney 293T cells were cultured in
Dulbecco’s modified Eagle’s medium supplemented with
10% fetal calf serum and seeded overnight at 50–60%
confluence in 96-well plates. Next day, the cells were
transiently co-transfected with Lipofectamine 2000 (Life-
technologies) and the following plasmids: pAR3-lux, that
contains three copies of the activin response element
(ARE) in the front of a luciferase reporter, which is spe-
cifically activated by nodal signaling; hDAND5;
hDAND5 R152H; hNODAL; hCRIPTO, a Nodal co-
receptor necessary for the proper activation of the Nodal
signaling; hFoxH1, the major transcriptional trans-
ducer of nodal signaling; CMV-β-Gal plasmid as control,
and various amounts of pCS2+ vector to maintain a con-
stant amount of total DNA. Transfections were performed
in triplicate and in three independent experiments with a
total amount of 100 ng DNA per well. Twenty-four hours
after transfection, luciferase activity was analyzed and the
activities were normalized to b-galactosidase control.
Western blot
Human embryonic kidney 293 T cells were transiently
transfected using lipofectamine 3000 (Thermo Fisher
Scientific) in Opti-MEM I reduced-serum medium
(Thermo Fisher Scientific). Cell lysates and conditioned
media were collected after 24 h, and protein expression
was monitored by Western blotting using polyclonal
goat anti-Cerl2 (R&D), and HRP- anti-goat (Sigma) anti-
bodies. Proteins were visualized using ECL detection re-
agent (Bio-Rad).
Statistical analysis
The data obtained from all analyses was statistically ana-
lyzed using GraphPad PRISM 5 software. Statistical
differences were determined by 2–tailed, unpaired Stu-
dent’s t-test. Probability values of P < 0.05 were consi-
dered significant.
Results
DNA from 38 unrelated children with congenital heart
defects arising from possible left-right defects and 40
ethnicity- and geographic-matched controls was direct
sequenced for the detection of variants in the two exons
of DAND5 gene. Sequence analysis of our patient’s co-
hort revealed a non-synonymous c.455G > A heterozy-
gous DAND5 variant in two patients (Fig. 1a), not
detected in in the control population. This alteration
was also present has heterozygous in the apparently nor-
mal mother of patient 2. Unfortunately, the father of pa-
tient 2 and the parents of patient 1 were not available
for sequencing. For validation, all exons were sequenced
using forward and reverse internal primers flanking the
missense variant. Clinically, patient 1 presented ventri-
cular septal defect with overriding aorta, pulmonary
atresia and left isomerism, while patient 2 presented
overriding aorta, ventricular septal defect, right ventricu-
lar hypertrophy and pulmonary atresia (a case of ex-
treme tetralogy of Fallot phenotype; Table 2). The
c.455G > A variant in exon 2 of DAND5 results in a
substitution of an Arginine residue for a Histidine
(p.R152H) localized in a highly conserved region of the
cysteine-rich DAN domain (Fig. 1b). Interestingly, the
DAND5 p.R152H variant had been already annotated in
the NCBI (http://www.ncbi.nlm.nih.gov) and Ensemble
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(http://www.ensembl.org) databases as Single Nucleotide
Variation (SNV - rs45513495), with a minor allele fre-
quency of ~1% (low-frequency variant; Table 3) and
described in ExAC database with an allele frequency of
0.01043 in all populations but never reported to be asso-
ciated with disease. To decide whether the detected
missense mutation is pathogenic or not, we use in silico
analysis tools (PolyPhen2, Mutation Taster, PROVEAN
and I-Mutant 3.0) and the results estimated differing
functional effect of this variant in DAND5 (Table 4).
Using the up-to-date PolyPhen-2 algorithm (http://genet-
ics.bwh.harvard.edu/pph2/index.shtml), we observed that
the DAND5 p.R152H variant had no effect on the DAND5
protein (classified as benign). Mutation Taster algorithm
(www.mutationtaster.org) predicted that this variant is a
polymorphism that might affect DAND5 protein features,
namely alterations in the cysteine-rich domain. Moreover,
PROVEAN software (http://provean.jcvi.org/) predicted a
deleterious effect (score − 2.84) on the proper function of
the DAND5 protein, and I-Mutant 3.0 predicted that the
a.a. alteration will largely reduce the stability of the protein
(a score of −1.28 a reliability index of 9; disease reliability
index of 3). To clarify the function of this protein
modification, we reproduced the p.R152H variant in an
expression vector containing the human DAND5
cDNA, and we evaluated the in vitro effect of p.R152H
in the regulation of Nodal activity using a well-
established Nodal-dependent luciferase assay as read-
out. This assay consists of a luciferase reporter gene
under the control of three activin-responsive elements
promoter, pAR3-lux, which is transcriptionally acti-
vated by Nodal signaling [21]. In addition, we used the
human version of the main intervenient genes, NODAL,
Fig. 1 a Forward and reverse DNA sequence chromatograms of patient 1 and 2 showing the c.455G > A allelic variant (highlighted by arrows).
b Schematic diagram of DAND5 structure with approximated localization of the variant identified in this study and cross-species sequence alignment
of DAND5 showing the conservation of amino acid R152 (highlighted by red box)
Table 2 Clinical and molecular findings of patient 1 and 2
Genotype Protein alteration Phenotype
Proband 1 DAND5 c.455GA DAND5 p.R152H Left isomerism;
VSD with overriding aorta;
Pulmonary atresia
Proband 2 DAND5 c.455GA DAND5 p.R152H Tetralogy of Fallot;
Pulmonary atresia
VSD – ventricular septal defect
Wild type DAND5 refseq. - NM_152654.2
Table 3 DAND5 c.455 G > A allele frequency according to ExAC
genome project
Gene Variant Variant rs number
DAND5 c.455 G > A / p.R152H 45513495
Population Allele frequency (%) Number of homozygous
/ heterozygous
European (Finnish) 2,4 2 / 155
European
(Non-Finnish)
1,5 14 / 990
All populations 1 16 / 1234
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CRYPTIC/CRIPTO, FOXH1, all necessary for a reliable
transduction of the levels of Nodal signaling in this type
of assay. The results, from triplicates of three independent
experiments, showed that the p.R152H DAND5 variant
causes a significant reduction in the normal NODAL-
inhibitory activity of DAND5 (Fig. 2). Moreover, a dose-
response at three different concentrations for the wild-
type vs. mutated protein confirms the reduced NODAL-
inhibitory activity of DAND5 (Additional file 1: Figure S1
and Additional file 2: Figure S2, being the two forms
equally produced upon transfection, Additional file 3:
Figure S3).
Discussion
The DNA sequencing analysis of our 38 unrelated
children and 40 control cohorts, revealed two patients,
patient 1 and patient 2, displaying the same variant in
DAND5 gene, not detected in the control population.
One of the patients presented ventricular septal defect
with overriding aorta, pulmonary atresia and left iso-
merism, while the other presented overriding aorta,
ventricular septal defect, right ventricular hypertrophy
and pulmonary atresia (a case of extreme tetralogy of
Fallot phenotype). The phenotypically normal mother of
patient 2 also presented heterozygosity the DAND5
c.455G > A variant, suggesting incomplete penetrance.
No others variants were detected neither in the DAND5
gene of the 38 patients nor control population. This sug-
gests that other variants in DAND5 might have a more
severe or lethal phenotype, or that due to its small
length DAND5 has less probability to randomly gain a
new alteration.
The functional effect of the variant, which leads to a
substitution of an arginine for a histidine in the position
152 of the highly conserved cysteine-rich DAN domain,
was inconclusive in the predicted analysis performed
with four different prediction algorithms. Nevertheless,
these algorithms have only an accuracy of 65–80% in the
prediction of known disease missense variants, being
even less accurate when examining missense variants
with milder effect [32]. Taking this in attention, we fur-
ther evaluated the effect of the DAND5 variant using a
Nodal-dependent luciferase assay. The results showed a
substantial decreased in the function of the DAND5
variant protein when compared to the wild-type
DAND5 protein. Since p.R152H is localized in the func-
tional domain of the DAND5 protein and because
DAND5 inhibits NODAL by direct binding [31], we
hypothesize that the protein alteration caused p.R152H
variation might interfere with the interaction efficiency
of DAND5-NODAL. Therefore, we further extrapolate
that, most probably, during the embryonic development
of patients with p.R152H DAND5, which has a DAND5
molecule with reduced activity, the overall activity of
NODAL on the node is above the proper levels. This
abnormal NODAL activity on the node might be
reflected then in excess of NODAL activity on the left-
lateral plate mesoderm and/or an ectopic expression of
NODAL and PITX2 on the right-lateral plate mesoderm
of the embryo. Interestingly, the phenotypes observed
in these two patients, are consistent with an ectopic ex-
pression of NODAL and PITX2 on the right side of the
embryo. Tetralogy of Fallot is a malformation of the
cardiac outflow tract (OFT) that comprises ventricular
septal defect, overriding of the aortic valve, right ven-
tricular outflow tract obstruction (pulmonary stenosis
or in its most severe form, pulmonary atresia), and




Mutation Taster Polymorphism Might affect protein features
PROVEAN -2,84 (cutoff = −2,5) Deleterious
I-Mutant 3.0 −1,28 Kcal/mol Reduced stability of the protein
and related to disease
Fig. 2 Functional analysis of DAND5 variant. The identified p.R152H
variant was evaluated through a luciferase assay as readout of Nodal
signaling. In this assay a luciferase reporter gene under the control
of three activin-responsive elements promoter, pAR3-lux, which is
transcriptionally activated by Nodal signaling, was used. The results,
from triplicates of three independent experiments, showed that the
p.R152H DAND5 variant leads to an increase of NODAL signaling
when compared to WT DAND5 protein. The effect of the different
genes altogether and the individual effect for each one are shown.
Data are shown as mean values from three independent experiments,
with the bars indicating the S.D. Asterisks: sample with a significant
difference (P < 0.01, t-test) calculated from comparison with wild-type
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right ventricular hypertrophy [33]. The OFT forms dur-
ing heart looping as a result of a coordinated process
uncompressing proliferation, differentiation, and migra-
tion of the pre-cardiac cells of the secondary heart field
(SHF). These cells are known to be sensitive to the
asymmetrically left expression of the NODAL and
PITX2 in the SHF [34]. Any imbalance in the LR pat-
terning that might lead to an ectopic right-sided ex-
pression and loss-of-function of PITX2 results in
reversed heart looping and abnormal shifting of the
OFT [35, 36], suggesting that anomalous LR body pat-
terning has the tendency to develop severe congenital
heart defects. Moreover, cases of entirely bilateral ex-
pression of NODAL and PITX2 in the cells of both left
and right lateral plate mesoderm lead to left isomerism
phenotypes, in which both atria present a left morph-
ology, commonly associated with atrioventricular septal
defects [37]. In agreement, it has been observed that
the absence of Cerl2 (DAND5 mouse homolog) in
Cerl2 KO mice leads to several cardiovascular malfor-
mations, including incomplete atrial and ventricular
septation, conotruncal defects, ventricular hypertrophy,
and/or to laterality defects like left isomerism and thor-
acic heterotaxy or situs inversus [30, 31].
ExAC database describes DAND5 p.R152H as a SNV,
detected in the heterozygous state in more than 1200 in-
dividuals, and present in 16 apparently normal homozy-
gotes. Indeed, the mother of patient 2 is phenotypically
normal but displays the DAND5 p.R152H variant in
hererozygosity. Nevertheless, we cannot exclude the
presence of a mild or undiagnosed heart defect on the
mother of patient 2, or on the subjects of the genome
projects, since detailed examination of these subjects is
rarely available. In addition, the ExAC database and the
American College of Medical Genetics and Genomics
warns to the fact that in these population databases the
presence of individuals with subclinical diseases among
the supposed healthy individuals leading to minor dis-
crepancies in some variant frequencies [32]. For ex-
ample, in a study conducted in Newcastle, 30% of the
patients (198/669 infants) were undiagnosed at the time
of discharge from the hospital, and in 30/198 the diag-
nosis was only made after death [38]. Moreover, some
phenotypes of CHD such as small atrial septal defects or
ventricular defects may be asymptomatic and undetected
throughout life [39]. Also, there are cases of apparently
normal individuals whose laterality defects were only de-
tected during adulthood [40]. Despite that, differences in
the overall level of functional Nodal pathway might be
explained by factors like differential allelic expressivity,
an incomplete penetrance, the presence of genetic mo-
difiers, and/or environmental factors. Interestingly, all
Cerl2 heterozygous mice are phenotypically normal, and
~40% of the Cerl2 homozygous KO mice become
normal adults, without any CHD and/or laterality defect
[31]. Therefore, we are not in the presence of a Mendel-
ian disorder. Moreover, the fact that 16 apparently nor-
mal homozygous individuals carry the DAND5 variant
suggests incomplete penetrance and sustains the multi-
factorial etiology and complex trait of CHD. This indi-
cates that the distribution and strength of the Cerl2
inhibitory signal, and ultimately the imbalance of the
dose-sensitive Nodal signaling, might be sensitized by
additional perturbations during LR patterning likewise it
was observed in other genes of the NODAL signaling
cascade [15, 17, 21]. For example, cryptic (CFC1 mouse
homolog) full-mutant mice presents randomization of
abdominal situs and complex cardiac malformations
such as atrial and septal defects, dextrocardia, DORV
and TGA, but a normal configuration of the OFT was
seen in one mutant [41]. In humans, it was identified
and classified as disease variant due to its loss-of-
function effect, a heterozygous single-base-pair deletion
(G174 del1) in CFC1 in two patients both with dextro-
cardia and TGA but one of the patients presented right
isomerism, whereas the other patient presented left
isomerism. This CFC1 variant was also reported in one
subject with sporadic DORV, ventricular septal defect,
aortic arch hypoplasia [15] and in a patient with tetral-
ogy of Fallot [17]. Interestingly, likewise we observed in
p.R152H DAND5 variant, the mothers of these CFC1
variant patients were found to carry the G174del1 alter-
ation but none presented any clinical phenotype, sug-
gesting incomplete penetrance. Accordingly, similar
cases of reduced penetrance have been reported in CHD
by others [25, 42].
Although the DAND5 p.R152H did not attest a spe-
cific genotype-phenotype link, our functional results
support a model in which the proper levels of Nodal sig-
naling, on both left- and right-lateral plate mesoderm,
are particularly sensitive to gene dosage effects for all
genes involved in the pathway. The imbalance in
dosage-sensitive Nodal signaling is a final common way
for laterality defects and associated CHDs.
Conclusions
In conclusion, we report a missense heterozygous vari-
ant, in the DAND5 gene of two unrelated Portuguese pa-
tients affected with congenital heart defects arising from
possible left-right defects. Although the prediction ana-
lysis was inconclusive, the localization of the variant, the
evolutionary conservation, and more importantly the
functional assay suggest a possible role of this variant in
the risk of disease. Our findings firstly prime DAND5 as
one of multiple candidate determinants involved in the
complex trait mechanism that causes CHDs, linking the
human vulnerability for CHDs and the reduced activity
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of heterozygous DAND5 p.R152H variant. Nevertheless,
an analysis of the DAND5 variant in a larger sample, to
confirm its true CHD risk, should not be excluded.
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decrease in the DAND5 protein activity when compared the DAND5
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(TIFF 60 kb)
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the mutant protein versus the wild type protein. The results confirm the
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(TIFF 60 kb)
Additional file 3: Figure S3. Western Blot of mouse wild-type and
mouse variant DAND5/Cerl2 protein. Since the available antibodies against
human DAND5/Cerl2 are not specific enough to detect the human protein,
we performed a western blot assay using lysates of cells transfected
with the mouse DAND5/Cerl2 WT and DAND5/Cerl2 variant proteins,
and no difference was observed in the protein production. Curiously,
the conditioned medium of the same cells showed a higher accumulation
of the DAND5/Cerl2 variant protein when compared to the DAND5/Cerl2
WT protein. CM – conditioned media; Mut – Mutant protein; WT – wild-type
protein. (TIFF 2995 kb)
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